Right Ventricular Function in End-stage Renal Disease Patients

Right ventricular (RV) dysfunction is a major cause of heart failure and mortality in end-stage renal disease (ESRD) patients. The aim of the study was to evaluate the long-term impacts of different dialysis modalities on RV function assessed by conventional echocardiography in ESRD patients with preserved left ventricular function. The study included 83 ESRD patients grouped as follows: peritoneal dialysis (PD; n=46) and hemodialysis with brachial arterio-venous fistula (HD; n=37). Conventional echocardiography including 2D and tissue Doppler imaging was performed in all patients. Echocardiographic parameters were compared between groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Transthoracic Echocardiography Hemodialysis

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Antalya Research and Training Hospital

Antalya, Turkey (Türkiye)

About this study

Cardiovascular diseases (CVD) are the main causes of death in patients undergoing dialysis. Right ventricular (RV) dysfunction is one of the major predictors of mortality and heart failure in this patient group. It has been shown that patients undergoing hemodialysis (HD) which is usually carried out via a surgically created arteriovenous fistula (AVF) have an increased risk for pulmonary hypertension and poorer right ventricular function compared with healthy controls . However, there are few data comparing the patients undergoing HD and peritoneal dialysis (PD), in terms of echocardiographic right ventricular function.

The aim of the present study was to elucidate the impact of both long term PD and HD therapy via brachial AVF on RV function in patients with preserved left ventricular (LV) function.

Patients undergoing dialysis were grouped as follows: 46 patients on PD and 37 patients on HD with brachial AVF. All of the study patients underwent transthoracic echocardiography. Left and right ventricular parameters were compared between two groups.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

End-stage renal disease patients on a regular dialysis program
Being on dialysis at least 6 months
>18 years old

Exclusion criteria

Ischemic heart disease
Left ventricular systolic dysfunction with an ejection fraction (EF) of less than 55 %
Valvulopathy
Left bundle branch block
Atrial fibrilation
Previous renal transplantation
Chronic obstructive pulmonary disease
Interstitial lung diseases
Connective tissue disorders
Chronic thromboembolic disease
Congenital left-to-right shunt
Primary pulmonary hypertension

Treatment and study plan

Transthoracic echocardiography

Diagnostic Test

Conventional 2-D transthoracic echocardiography was performed to all patients

Primary outcomes

Estimation of right ventricular function in end-stage renal disease patients

Time frame: 1 week

Transthoracic echocardiography was performed to end-stage renal disease patients on hemodialysis and peritoneal dialysis for at least 6 months. Tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (RV FAC), Right ventricular myocardial performance index (RV MPI) and right ventricular lateral peak annular systolic velocity (Sa) were measured to estimate right ventricular function.

Sponsors and collaborators

Lead sponsor

Antalya Training and Research Hospital

Other Gov

Registry information

Official study title

The Impact of Different Dialysis Modalities on Right Ventricular Function in End-stage Renal Disease Patients

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Aug 24, 2020
Registry last updated: Aug 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed